Abstract
Colorectal cancer (CRC) is a major health problem causing significant morbidity and mortality. During the last decade, results from different studies indicate that the pathogenetic mechanisms of CRC encompass tumour microenvironment, emphasizing a tight correlation with aging, inflammation, nutrition, gut microbiome composition and epigenetic modifications. Aging is one of the most important risk factors for the development of a wide range of neoplasies, including CRC, as it represents the general framework in which the tumor environment evolves. Together, these elements likely contribute to the carcinogenic process with specific effects, impacts and roles in the different stages of the tumor progression. CRCs evolve through loops of deregulated inflammatory stimuli which are sustained by DNA damage signaling pathways, dysbiosis of gut microbiota (GM) and epigenetic re-modelling (DNA methylation). To date no studies address those elements simultaneously. The synergic analysis of such parameters could provide new biological insights and effective biomarkers that could have applications in prevention, molecular diagnosis, prognosis and treatment of CRC.
Keywords: Colorectal cancer, inflammation, aging, gut microbiota, epigenetic, nutrition
Current Pharmaceutical Design
Title:Colorectal Cancer Microenvironment: Among Nutrition, Gut Microbiota, Inflammation and Epigenetics
Volume: 19 Issue: 4
Author(s): Paolo Garagnani, Chiara Pirazzini, Claudio Franceschi
Affiliation:
Keywords: Colorectal cancer, inflammation, aging, gut microbiota, epigenetic, nutrition
Abstract: Colorectal cancer (CRC) is a major health problem causing significant morbidity and mortality. During the last decade, results from different studies indicate that the pathogenetic mechanisms of CRC encompass tumour microenvironment, emphasizing a tight correlation with aging, inflammation, nutrition, gut microbiome composition and epigenetic modifications. Aging is one of the most important risk factors for the development of a wide range of neoplasies, including CRC, as it represents the general framework in which the tumor environment evolves. Together, these elements likely contribute to the carcinogenic process with specific effects, impacts and roles in the different stages of the tumor progression. CRCs evolve through loops of deregulated inflammatory stimuli which are sustained by DNA damage signaling pathways, dysbiosis of gut microbiota (GM) and epigenetic re-modelling (DNA methylation). To date no studies address those elements simultaneously. The synergic analysis of such parameters could provide new biological insights and effective biomarkers that could have applications in prevention, molecular diagnosis, prognosis and treatment of CRC.
Export Options
About this article
Cite this article as:
Paolo Garagnani, Chiara Pirazzini, Claudio Franceschi , Colorectal Cancer Microenvironment: Among Nutrition, Gut Microbiota, Inflammation and Epigenetics, Current Pharmaceutical Design 2013; 19 (4) . https://dx.doi.org/10.2174/1381612811306040765
DOI https://dx.doi.org/10.2174/1381612811306040765 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Long-circulating Targeted Nanoparticles for Cancer Therapy
Current Nanoscience Advances in the Development of Multimodal Imaging Agents for Nuclear/Near-infrared Fluorescence Imaging
Current Medicinal Chemistry Capillary Electrophoresis–Mass Spectrometry in Metabolomics: The Potential for Driving Drug Discovery and Development
Current Drug Metabolism Genomic Instability and Cancer
Current Molecular Medicine A New Synthesis for Acacetin, Chrysoeriol, Diosmetin, Tricin and Other Hydroxylated Flavones by Modified Baker-Venkataraman Transformation
Letters in Organic Chemistry Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice
Current Cancer Drug Targets P38 MAPK Contributes to Resistance and Invasiveness of HER2- Overexpressing Breast Cancer
Current Medicinal Chemistry n-3 Polyunsaturated Fatty Acids as Signal Transduction Modulators and Therapeutical Agents in Cancer
Current Signal Transduction Therapy Arylpyrazoles: Heterocyclic Scaffold of Immense Therapeutic Application
Current Organic Chemistry Prevention and Treatment of Regimen-Related Mucosal Toxicity
Recent Patents on Anti-Cancer Drug Discovery Nanocarriers for Anticancer Drugs - New Trends in Nanomedicine
Current Drug Metabolism Clinical Experience with Antiangiogenic Therapy in Leukemia
Current Cancer Drug Targets Chemical Space of FLT3 Inhibitors as Potential Anti-AML Drugs
Recent Patents on Anti-Cancer Drug Discovery Reversal of Multidrug Resistance by Natural Substances from Plants
Current Topics in Medicinal Chemistry Applications of Important Polysaccharides in Drug Delivery
Current Pharmaceutical Design Epigenetic Modifications of the Nuclear Factor Kappa B Signalling Pathway and its Impact on Inflammatory Bowel Disease
Current Pharmaceutical Design Epigenetics, Depression and Antidepressant Treatment
Current Pharmaceutical Design The Role of dUTPase and Uracil-DNA Repair in Cancer Chemotherapy
Current Protein & Peptide Science The MRP Family and Anticancer Drug Metabolism
Current Drug Metabolism Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment
Current Cancer Drug Targets